Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

28.57 -0.04 (-0.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

December 21, 2023

On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.

Via Investor's Business Daily

Why NASDAQ:AMPH qualifies as a high growth stock. ↗

December 12, 2023

Why the growth investor may take a look at AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH).

Via Chartmill

TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

December 07, 2023

TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.

Via Investor's Business Daily

Exploring NASDAQ:AMPH's CANSLIM characteristics. ↗

December 05, 2023

Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing?

Via Chartmill

These Three Biotech Stocks Are Trading At A Discount ↗

November 23, 2023

Investors exposed to the biotech sector have seen mixed results this year.

Via Talk Markets

Exploring growth characteristics of AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH). ↗

November 21, 2023

Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.

Via Chartmill

Evaluating NASDAQ:AMPH for Growth Investment Opportunities. ↗

November 14, 2023

High growth, ROE and relative strength for AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), growth investors may appreciate this.

Via Chartmill

Recap: Amphastar Pharma Q3 Earnings ↗

November 08, 2023

Via Benzinga

Earnings Preview For Amphastar Pharma ↗

November 07, 2023

Via Benzinga

Amphastar Pharma: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade ↗

November 10, 2023

Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.

Via Investor's Business Daily

7 Healthcare Stocks That Are Poised to Become the Next Unicorns ↗

November 09, 2023

Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.

Via InvestorPlace

Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday ↗

November 09, 2023

U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗

November 08, 2023

On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.

Via Investor's Business Daily

Earnings Outlook For Amphastar Pharma ↗

May 08, 2023

Via Benzinga

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗

October 31, 2023

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 ↗

October 16, 2023

Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating ↗

September 27, 2023

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 11, 2023

Via Benzinga

Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why ↗

August 17, 2023

Eli Lilly and Company (LLY) boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer.

Via Talk Markets

Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 12, 2023

Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.

Via Benzinga

Abcam Stock Earns Relative Strength Rating Upgrade ↗

June 20, 2023

A Relative Strength Rating upgrade for Abcam ADR shows improving technical performance.

Via Investor's Business Daily

FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

June 06, 2023

On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier.

Via Investor's Business Daily

Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating ↗

May 03, 2023

On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday.

Via Investor's Business Daily

Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash ↗

April 24, 2023

Via Benzinga

Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

April 17, 2023

On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.

Via Investor's Business Daily

Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move ↗

April 10, 2023

Via Benzinga

BioMarin Pharmaceutical Stock Shows Rising Relative Strength ↗

March 30, 2023

BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier.

Via Investor's Business Daily

Alkermes Stock Sees Rising Relative Strength Rating ↗

March 28, 2023

The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77.

Via Investor's Business Daily

Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark ↗

March 27, 2023

In a welcome move, Exelixis stock saw its Relative Strength Rating improve to 73 on Monday, up from 69 a day earlier.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today